Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

305
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
305
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

671
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
671
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Impact of the albumin-bilirubin score on short- and long-term mortality in native and prosthetic valve endocarditis ALBI score and mortality in native and prosthetic valve endocarditis.

Acta cardiologica·2026
Same author

Prognostic value of the NAPLES score in patients undergoing LVAD implantation: comparison with established nutritional indices.

BMC cardiovascular disorders·2026
Same author

Catheter ablation of typical atrial flutter in a patient with left ventricular assist device support: a case report.

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology·2026
Same author

Reply to the Letter to the Editor: "Integrated Clinical, Multimodality Imaging, and Electrophysiological Markers for Improved Prediction of Sudden Cardiac Death in Hypertrophic Cardiomyopathy".

Anatolian journal of cardiology·2026
Same author

Transcatheter ventricular septal defect closure in children: ten-year experience with multiple devices and long-term outcomes.

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology·2026
Same author

Re: Association of Material Hardship and Clinical Outcomes in Infants with Congenital Heart Disease.

Pediatric cardiology·2026

相关实验视频

Updated: Jan 11, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K

从模式到预后:高级心力衰竭中的机器学习衍生集群.

Murat Karaçam1, Barkın Kültürsay2, Deniz Mutlu3

  • 1Department of Cardiology, Bitlis State Hospital, Bitlis, Türkiye.

Frontiers in cardiovascular medicine
|November 10, 2025
PubMed
概括

机器学习确定了两个高级心力衰竭 (HF) 现型. 一组血液动力学和预后更好,而另一组由于双心脏功能障碍和运动能力低下而面临更高的死亡风险.

关键词:
晚期心力衰竭是什么意思机器学习是机器学习.现型定制 现型定制 现型定制风险分层的分层是风险分层.没有监督的集群聚类.

相关实验视频

Last Updated: Jan 11, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K

科学领域:

  • 心脏病学 心脏病学
  • 计算生物学 计算生物学
  • 医疗信息学 医疗信息学

背景情况:

  • 晚期心力衰竭 (HF) 呈现出复杂的异质性,挑战传统的预后和个性化治疗.
  • 现有的分类系统可能无法完全捕捉到针对高级高频患者量身定制的患者护理所需的细微差别.

研究的目的:

  • 采用无监督机器学习来识别高级HF患者中不同的临床子组.
  • 评估这些已识别的表型对长期临床结果的预后影响.

主要方法:

  • 对524名晚期HF患者的回顾性分析,具有全面的临床,心声学,血液动力学和运动数据.
  • K-意味着对标准化的多维数据应用集群,以定义患者表型.
  • 卡普兰-梅尔分析和考克斯回归用于评估结果 (死亡率,LVAD,移植) 按集群.

主要成果:

  • 通过聚类确定了两个不同的表型.
  • 集群1:患者血液动力学和功能状况保持良好,与良好的预后相关.
  • 集群2:患有双心脏功能障碍,肺压升高和运动能力降低的老年患者,显着更高的不良事件发生率 (HR: 3.84; p < 0.001).

结论:

  • 机器学习成功地划分了两个先进的HF表型,具有不同的临床特征和预后.
  • 这种数据驱动的表型化方法为在先进的高频中改善风险分层提供了潜力.
  • 这些发现可以指导为这种脆弱患者群体开发个性化治疗策略.